Cargando…
The HDL particle composition determines its antitumor activity in pancreatic cancer
Despite enormous efforts to improve therapeutic options, pancreatic cancer remains a fatal disease and is expected to become the second leading cause of cancer-related deaths in the next decade. Previous research identified lipid metabolic pathways to be highly enriched in pancreatic ductal adenocar...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112193/ https://www.ncbi.nlm.nih.gov/pubmed/35577388 http://dx.doi.org/10.26508/lsa.202101317 |
_version_ | 1784709370105298944 |
---|---|
author | Oberle, Raimund Kührer, Kristina Österreicher, Tamina Weber, Florian Steinbauer, Stefanie Udonta, Florian Wroblewski, Mark Ben-Batalla, Isabel Hassl, Ingrid Körbelin, Jakob Unseld, Matthias Jauhiainen, Matti Plochberger, Birgit Röhrl, Clemens Hengstschläger, Markus Loges, Sonja Stangl, Herbert |
author_facet | Oberle, Raimund Kührer, Kristina Österreicher, Tamina Weber, Florian Steinbauer, Stefanie Udonta, Florian Wroblewski, Mark Ben-Batalla, Isabel Hassl, Ingrid Körbelin, Jakob Unseld, Matthias Jauhiainen, Matti Plochberger, Birgit Röhrl, Clemens Hengstschläger, Markus Loges, Sonja Stangl, Herbert |
author_sort | Oberle, Raimund |
collection | PubMed |
description | Despite enormous efforts to improve therapeutic options, pancreatic cancer remains a fatal disease and is expected to become the second leading cause of cancer-related deaths in the next decade. Previous research identified lipid metabolic pathways to be highly enriched in pancreatic ductal adenocarcinoma (PDAC) cells. Thereby, cholesterol uptake and synthesis promotes growth advantage to and chemotherapy resistance for PDAC tumor cells. Here, we demonstrate that high-density lipoprotein (HDL)–mediated efficient cholesterol removal from cancer cells results in PDAC cell growth reduction and induction of apoptosis in vitro. This effect is driven by an HDL particle composition–dependent interaction with SR-B1 and ABCA1 on cancer cells. AAV-mediated overexpression of APOA1 and rHDL injections decreased PDAC tumor development in vivo. Interestingly, plasma samples from pancreatic-cancer patients displayed a significantly reduced APOA1-to-SAA1 ratio and a reduced cholesterol efflux capacity compared with healthy donors. We conclude that efficient, HDL-mediated cholesterol depletion represents an interesting strategy to interfere with the aggressive growth characteristics of PDAC. |
format | Online Article Text |
id | pubmed-9112193 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Life Science Alliance LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-91121932022-05-27 The HDL particle composition determines its antitumor activity in pancreatic cancer Oberle, Raimund Kührer, Kristina Österreicher, Tamina Weber, Florian Steinbauer, Stefanie Udonta, Florian Wroblewski, Mark Ben-Batalla, Isabel Hassl, Ingrid Körbelin, Jakob Unseld, Matthias Jauhiainen, Matti Plochberger, Birgit Röhrl, Clemens Hengstschläger, Markus Loges, Sonja Stangl, Herbert Life Sci Alliance Research Articles Despite enormous efforts to improve therapeutic options, pancreatic cancer remains a fatal disease and is expected to become the second leading cause of cancer-related deaths in the next decade. Previous research identified lipid metabolic pathways to be highly enriched in pancreatic ductal adenocarcinoma (PDAC) cells. Thereby, cholesterol uptake and synthesis promotes growth advantage to and chemotherapy resistance for PDAC tumor cells. Here, we demonstrate that high-density lipoprotein (HDL)–mediated efficient cholesterol removal from cancer cells results in PDAC cell growth reduction and induction of apoptosis in vitro. This effect is driven by an HDL particle composition–dependent interaction with SR-B1 and ABCA1 on cancer cells. AAV-mediated overexpression of APOA1 and rHDL injections decreased PDAC tumor development in vivo. Interestingly, plasma samples from pancreatic-cancer patients displayed a significantly reduced APOA1-to-SAA1 ratio and a reduced cholesterol efflux capacity compared with healthy donors. We conclude that efficient, HDL-mediated cholesterol depletion represents an interesting strategy to interfere with the aggressive growth characteristics of PDAC. Life Science Alliance LLC 2022-05-16 /pmc/articles/PMC9112193/ /pubmed/35577388 http://dx.doi.org/10.26508/lsa.202101317 Text en © 2022 Oberle et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Articles Oberle, Raimund Kührer, Kristina Österreicher, Tamina Weber, Florian Steinbauer, Stefanie Udonta, Florian Wroblewski, Mark Ben-Batalla, Isabel Hassl, Ingrid Körbelin, Jakob Unseld, Matthias Jauhiainen, Matti Plochberger, Birgit Röhrl, Clemens Hengstschläger, Markus Loges, Sonja Stangl, Herbert The HDL particle composition determines its antitumor activity in pancreatic cancer |
title | The HDL particle composition determines its antitumor activity in pancreatic cancer |
title_full | The HDL particle composition determines its antitumor activity in pancreatic cancer |
title_fullStr | The HDL particle composition determines its antitumor activity in pancreatic cancer |
title_full_unstemmed | The HDL particle composition determines its antitumor activity in pancreatic cancer |
title_short | The HDL particle composition determines its antitumor activity in pancreatic cancer |
title_sort | hdl particle composition determines its antitumor activity in pancreatic cancer |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112193/ https://www.ncbi.nlm.nih.gov/pubmed/35577388 http://dx.doi.org/10.26508/lsa.202101317 |
work_keys_str_mv | AT oberleraimund thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT kuhrerkristina thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT osterreichertamina thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT weberflorian thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT steinbauerstefanie thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT udontaflorian thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT wroblewskimark thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT benbatallaisabel thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT hasslingrid thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT korbelinjakob thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT unseldmatthias thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT jauhiainenmatti thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT plochbergerbirgit thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT rohrlclemens thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT hengstschlagermarkus thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT logessonja thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT stanglherbert thehdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT oberleraimund hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT kuhrerkristina hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT osterreichertamina hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT weberflorian hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT steinbauerstefanie hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT udontaflorian hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT wroblewskimark hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT benbatallaisabel hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT hasslingrid hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT korbelinjakob hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT unseldmatthias hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT jauhiainenmatti hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT plochbergerbirgit hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT rohrlclemens hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT hengstschlagermarkus hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT logessonja hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer AT stanglherbert hdlparticlecompositiondeterminesitsantitumoractivityinpancreaticcancer |